

STAND. COM. REP. NO.

1262

Honolulu, Hawaii

March 24, 2017

RE: S.B. No. 505
S.D. 1
H.D. 1

Honorable Joseph M. Souki
Speaker, House of Representatives
Twenty-Ninth State Legislature
Regular Session of 2017
State of Hawaii

Sir:

Your Committee on Health, to which was referred S.B. No. 505,
S.D. 1, entitled:

"A BILL FOR AN ACT RELATING TO HEALTH,"

begs leave to report as follows:

The purpose of this measure is to establish additional
safeguards for the use of prescription opioids to reduce instances
of dependency, overdose, and death.

Specifically, this measure:

- (1) Requires execution of an informed consent process,
subject to administration and monitoring by the
Department of Health, between a patient and prescribing
practitioner in circumstances that carry an elevated
risk of creating dependency;
- (2) Establishes quantitative limits on opioid and
benzodiazepine prescriptions, subject to specified
exceptions; and
- (3) Clarifies the Board of Nursing's authority to enforce
compliance with the Uniform Controlled Substance Act.

SB505 HD1 HSCR HLT HMS 2017-3143



Your Committee received testimony in support of this measure from Early Childhood Action Strategy. Your Committee received testimony in opposition to this measure from the Department of Health, The Drug Policy Forum of Hawai'i, CHOW Project, and American Congress of Obstetricians and Gynecologists. The Department of Public Safety, Hawaii Medical Board, The Queen's Health Systems, Hawaii Medical Association, American Cancer Society Cancer Action Network, Hawaii College of Emergency Physicians, Hawaii Substance Abuse Coalition, American Society of Clinical Oncology, and Hawaii Society of Clinical Oncology submitted comments.

Your Committee has amended this measure by:

- (1) Deleting redundant language relating to prescriber registration with the controlled substance electronic prescription accountability system;
- (2) Clarifying that the currently allowable use of narcotic drugs for detoxification treatment refers to use in the process of medically managed withdrawal;
- (3) Changing its effective date to July 1, 2070, to promote further discussion; and
- (4) Making technical, nonsubstantive amendments for the purpose of clarity and consistency.

As affirmed by the record of votes of the members of your Committee on Health that is attached to this report, your Committee is in accord with the intent and purpose of S.B. No. 505, S.D. 1, as amended herein, and recommends that it pass Second Reading in the form attached hereto as S.B. No. 505, S.D. 1, H.D. 1, and be referred to your Committee on Consumer Protection & Commerce.



Respectfully submitted on
behalf of the members of the
Committee on Health,

Debra A. Belatti

DELLA AU BELATTI, Chair



